Shionogi Signs a Research Collaboration with UBE Industries for the Development of Anti-RS Virus Drug Candidates

 Shionogi Signs a Research Collaboration with UBE Industries for the Development of Anti-RS Virus Drug Candidates

Shionogi Signs a Research Collaboration with UBE Industries for the Development of Anti-RS Virus Drug Candidates

Shots:

  • Shionogi and UBE Industries collaborates for development of anti-RS (respiratory syncytial) virus drugs to treat Respiratory Syncytial Virus (RSV) infection
  • The focus of the agreement is to combine Shionogi’s drug discovery platform with UBE’s drug design technology for SAR (Structure-Activity Relationship) study
  • UBE Industries’ Drug discovery platform uses polymer synthesis technology for the development of drug candidates in multiple therapeutic area

Click here to read full press release/ article | Ref: Shionogi | Image: Japan Products

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post